Comparative study of HC2 and Cervista™ for the detection of HPV

Francesc Alameda; Beatriz Bellosillo; Belén Lloveras; Merce Muset; Gemma Mancebo; Fernando Larrazabal; Ramón Carreras; Sergi Serrano

doi:10.1016/j.patol.2011.07.002

Comparative study of HC2 and Cervista™ for the detection of HPV

Francesc Alameda, Beatriz Bellosillo, Belén Lloveras, Merce Muset, Gemma Mancebo, Fernando Larrazabal, Ramón Carreras, Sergi Serrano

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Introduction: HPV detection in gynaecological samples currently provides key data in cervical pathology for diagnostic and management decisions. At present HC2 is the most clinically proven method for this purpose. Methods: Comparative study of HPV-HR detection between HC2 and Cervista™. Results: The concordance between the two methods is 96.4%. The sensitivity of Cervista™ for CIN2+ is 98.3% and specificity exceeds 98.4%. Conclusions: We conclude that Cervista™ is an appropriate method for the detection of HPV-HR in gynecological samples for screening and clinical purposes. © 2011 SEAP y SEC.

Original language	English
Pages (from-to)	191-194
Journal	Revista Espanola de Patologia
Volume	44
Issue number	4
DOIs	https://doi.org/10.1016/j.patol.2011.07.002
Publication status	Published - 1 Oct 2011

Keywords

Cervical pathology
Detection
Human papilomavirus (HPV)
Screening

Access to Document

10.1016/j.patol.2011.07.002

Fingerprint Dive into the research topics of 'Comparative study of HC2 and Cervista™ for the detection of HPV'. Together they form a unique fingerprint.

Cite this

@article{ab730d05f521448e804a61e743b93b82,

title = "Comparative study of HC2 and Cervista{\texttrademark} for the detection of HPV",

abstract = "Introduction: HPV detection in gynaecological samples currently provides key data in cervical pathology for diagnostic and management decisions. At present HC2 is the most clinically proven method for this purpose. Methods: Comparative study of HPV-HR detection between HC2 and Cervista{\texttrademark}. Results: The concordance between the two methods is 96.4%. The sensitivity of Cervista{\texttrademark} for CIN2+ is 98.3% and specificity exceeds 98.4%. Conclusions: We conclude that Cervista{\texttrademark} is an appropriate method for the detection of HPV-HR in gynecological samples for screening and clinical purposes. {\textcopyright} 2011 SEAP y SEC.",

keywords = "Cervical pathology, Detection, Human papilomavirus (HPV), Screening",

author = "Francesc Alameda and Beatriz Bellosillo and Bel{\'e}n Lloveras and Merce Muset and Gemma Mancebo and Fernando Larrazabal and Ram{\'o}n Carreras and Sergi Serrano",

year = "2011",

month = oct,

day = "1",

doi = "10.1016/j.patol.2011.07.002",

language = "English",

volume = "44",

pages = "191--194",

journal = "Revista Espanola de Patologia",

issn = "1699-8855",

publisher = "Ediciones Doyma, S.L.",

number = "4",

}

TY - JOUR

T1 - Comparative study of HC2 and Cervista™ for the detection of HPV

AU - Alameda, Francesc

AU - Bellosillo, Beatriz

AU - Lloveras, Belén

AU - Muset, Merce

AU - Mancebo, Gemma

AU - Larrazabal, Fernando

AU - Carreras, Ramón

AU - Serrano, Sergi

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Introduction: HPV detection in gynaecological samples currently provides key data in cervical pathology for diagnostic and management decisions. At present HC2 is the most clinically proven method for this purpose. Methods: Comparative study of HPV-HR detection between HC2 and Cervista™. Results: The concordance between the two methods is 96.4%. The sensitivity of Cervista™ for CIN2+ is 98.3% and specificity exceeds 98.4%. Conclusions: We conclude that Cervista™ is an appropriate method for the detection of HPV-HR in gynecological samples for screening and clinical purposes. © 2011 SEAP y SEC.

AB - Introduction: HPV detection in gynaecological samples currently provides key data in cervical pathology for diagnostic and management decisions. At present HC2 is the most clinically proven method for this purpose. Methods: Comparative study of HPV-HR detection between HC2 and Cervista™. Results: The concordance between the two methods is 96.4%. The sensitivity of Cervista™ for CIN2+ is 98.3% and specificity exceeds 98.4%. Conclusions: We conclude that Cervista™ is an appropriate method for the detection of HPV-HR in gynecological samples for screening and clinical purposes. © 2011 SEAP y SEC.

KW - Cervical pathology

KW - Detection

KW - Human papilomavirus (HPV)

KW - Screening

U2 - 10.1016/j.patol.2011.07.002

DO - 10.1016/j.patol.2011.07.002

M3 - Article

VL - 44

SP - 191

EP - 194

JO - Revista Espanola de Patologia

JF - Revista Espanola de Patologia

SN - 1699-8855

IS - 4

ER -